Werewolf Therapeutics obtains exclusive EMD license for WTX-124, WTX-330
Hammerstone MarketTalk reports that HOWL Werewolf Therapeutics obtains an exclusive license from EMD for the development of WTX-124 and WTX-330, as stated in an SEC filing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.